Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcadia Biosciences's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 35.26.
Arcadia Biosciences's Days Inventory for the
three
months ended in Mar. 2026 was 133.75.
Arcadia Biosciences's Days Payable for the
three
months ended in Mar. 2026 was 166.53.
Therefore, Arcadia Biosciences's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 2.48.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Arcadia Biosciences Cash Conversion Cycle Related Terms
Arcadia Biosciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RKDA vs ORISF, ARRT, CIMG: Cash Conversion Cycle Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences Cash Conversion Cycle vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Arcadia Biosciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences (RKDA) has a Cash Conversion Cycle of 2.48 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Arcadia Biosciences and its competitors.
Is Arcadia Biosciences' Cash Conversion Cycle too high?
Arcadia Biosciences' current Cash Conversion Cycle is 2.48. The Consumer Packaged Goods industry median Cash Conversion Cycle is 74.98. Arcadia Biosciences' value of 2.48 is 96.7% below this industry median. Overall, Arcadia Biosciences has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' Cash Conversion Cycle compare to ORISF and ARRT?
Arcadia Biosciences' Cash Conversion Cycle of 2.48 can be compared against companies in the Consumer Packaged Goods industry. The industry median Cash Conversion Cycle is 74.98. Arcadia Biosciences' value of 2.48 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Consumer Packaged Goods company?
The median Cash Conversion Cycle among Consumer Packaged Goods companies is 74.98, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcadia Biosciences's current Cash Conversion Cycle of 2.48 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Arcadia Biosciences and its competitors. For the Consumer Packaged Goods industry, the median Cash Conversion Cycle is 74.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcadia Biosciences's current Cash Conversion Cycle is 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcadia Biosciences (RKDA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.84, compared to a current price of $0.56 — trading 80.3% below its estimated fair value. The current Cash Conversion Cycle is 2.48 and 96.7% below the Consumer Packaged Goods industry median of 74.98. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Arcadia Biosciences (RKDA), the current Cash Conversion Cycle is 2.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (RKDA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of $0.56 is trading 80.3% below its estimated GF Value™ of $2.84.
GuruFocus considers Arcadia Biosciences to be Possible Value Trap.
Key valuation signals for RKDA:
Cash Conversion Cycle: 2.48
GF Value™: $2.84 vs. price of $0.56 (80.3% below fair value)
Industry Position: 96.7% below the Consumer Packaged Goods median
No single metric tells the full story. See the RKDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for RKDA
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RKDA has been successfully added to your 
